Ozempic Gastroparesis Lawsuit: Navigating the Complexities of MDL 3094
Estimated reading time: 8 minutes
- Ozempic (semaglutide) faces thousands of lawsuits alleging inadequate warnings about gastroparesis.
- MDL 3094 consolidates claims against Novo Nordisk and other manufacturers of GLP-1 receptor agonists.
- Plaintiffs report severe gastrointestinal complications, impacting quality of life.
- Litigation involves key rulings on evidence and potential multi-billion dollar implications.
- The case highlights the importance of pharmaceutical transparency and robust risk assessment.
Ozempic Gastroparesis Lawsuit: A Growing Concern
The weight-loss drug Ozempic (semaglutide), manufactured by Novo Nordisk, is facing a significant legal battle. Thousands of lawsuits claim the company failed to adequately warn patients about the risk of severe gastrointestinal side effects, particularly gastroparesis, a condition causing delayed stomach emptying. Multidistrict Litigation (MDL) 3094 in the Eastern District of Pennsylvania consolidates these claims, encompassing over 2,676 lawsuits (as of September 2025). These lawsuits also include claims related to ileus and intestinal blockage, and extend to other GLP-1 receptor agonist drugs like Wegovy, Rybelsus, Mounjaro, and Trulicity, involving companies such as Eli Lilly.
Key Allegations and the Impact on Patients
The core allegation is a failure to warn. Plaintiffs argue Novo Nordisk knew, or should have known, about the risk of severe gastrointestinal side effects but failed to provide sufficient warnings. The consequences of Ozempic-induced gastroparesis are debilitating, including persistent vomiting, nausea, severe abdominal pain, bloating, and significant weight loss. The case of Jaclyn Bjorklund highlights the severity, alleging severe gastroparesis, persistent vomiting, and even tooth loss due to acid reflux from Ozempic and Mounjaro use.
Litigation Status and Key Developments
MDL 3094, established in February 2024 under Judge Karen Spencer Marston, centralizes pretrial proceedings. A significant August 2025 ruling mandates gastric emptying studies for plaintiffs claiming gastroparesis. Novo Nordisk denies the claims, but independent analyses project potentially significant financial implications, with some estimations reaching $2 billion. The FDA’s addition of specific warnings for intestinal blockage and ileus in September 2023 further underscores the growing awareness of these risks.
Beyond Gastroparesis: Other Potential Claims
Beyond gastrointestinal issues, separate litigation concerns Ozempic vision loss (NAION), with 21 lawsuits pending in New Jersey as of September 2025. Further investigation is underway into other potential side effects, including pancreatitis, pancreatic cancer, gallbladder issues, and thyroid problems.
- Enhanced Risk Assessment
- Robust Warning Labels
- Regulatory Compliance
- Proactive Communication
Conclusion and Call to Action
The Ozempic gastroparesis lawsuit underscores the importance of proactive risk management, robust warning labels, and patient safety. Understanding this litigation is crucial for patients and businesses. Our legal experts offer guidance in navigating pharmaceutical litigation.